Efficacy and safety of fruquintinib plus sintilimab in third-line treatment of metastatic colorectal cancer: A single-center experience

doi:10.4251/wjgo.v18.i6.117101

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 6

This Article

(4)

(0)

(26)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Jun 15, 2026; 18(6): 117101
Published online Jun 15, 2026. doi: 10.4251/wjgo.v18.i6.117101

Efficacy and safety of fruquintinib plus sintilimab in third-line treatment of metastatic colorectal cancer: A single-center experience

Jun Pan, Ping Li, Yi Zhao, Yu-He Zhou, Ying Zhao, Tian-Long Zhang, Yi-Tian Chen, Xiao-Yuan Chu

Jun Pan, Yi-Tian Chen, Xiao-Yuan Chu, Department of Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China

Ping Li, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China

Ping Li, Gastric Cancer Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China

Yi Zhao, Department of Medical Oncology, Nanjing Tianyinshan Hospital Affiliated to China Pharmaceutical University, Nanjing 211106, Jiangsu Province, China

Yu-He Zhou, Department of General Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China

Ying Zhao, Department of Radiology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China

Tian-Long Zhang, Department of Clinical Laboratory, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China

Co-first authors: Jun Pan and Ping Li.

Co-corresponding authors: Yi-Tian Chen and Xiao-Yuan Chu.

Author contributions: Pan J and Li P drafted the manuscript and made equal contributions as co-first authors; Li P, Zhao Y, and Zhang TL acquired the data; Pan J analyzed and interpreted pathology; Zhao Y and Zhou YH analyzed and interpreted the imaging findings; Pan J, Li P, Chen YT, and Chu XY contributed to the study conception and design; Chen YT and Chu XY made equal contributions as co-corresponding authors; all authors approved the final version to publish.

Supported by Beijing Bethune Foundation, No. 2024-YJ-220-J-010.

Institutional review board statement: This study was approved by the Ethics Committee of The First Affiliated Hospital of Nanjing Medical University, No. 2025-SRFA-899.

Informed consent statement: The written informed consent to participate was obtained from all the patients.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Data sharing statement: The datasets generated and analyzed during the present study are available from the corresponding author on reasonable request.

Corresponding author: Xiao-Yuan Chu, MD, Department of Oncology, Jinling Hospital, Medical School of Nanjing University, No. 305 Zhongshan East Road, Nanjing 210002, Jiangsu Province, China. chuxiaoyuan0@163.com

Received: November 28, 2025
Revised: January 5, 2026
Accepted: February 28, 2026
Published online: June 15, 2026
Processing time: 193 Days and 19.5 Hours

Core Tip

Core Tip: This study evaluated the safety and efficacy of fruquintinib plus sintilimab in third-line treatment of metastatic colorectal cancer (mCRC). One patient achieved complete response, one had stable disease, and four experienced progressive disease. Median progression-free survival was 3.8 months, and median overall survival was 5.7 months. Fruquintinib combined with sintilimab was well tolerated. Common adverse reactions included bone marrow suppression, liver function impairment, and hypothyroidism, predominantly grades 1-2. Fruquintinib combined with sintilimab as a third-line treatment for mCRC appeared effective in patients with microsatellite stable mCRC and a low tumor burden, who experienced a survival benefit. This treatment warrants further exploration.